Our top pick for
Gossamer Bio Inc is a biotechnology business based in the US. Gossamer Bio shares (GOSS) are listed on the NASDAQ and all prices are listed in US Dollars. Gossamer Bio employs 195 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$12.75|
|52-week range||$7.04 - $14.30|
|50-day moving average||$11.98|
|200-day moving average||$9.39|
|Wall St. target price||$19.57|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.26|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||0.24%|
|1 month (2021-09-27)||-1.32%|
|3 months (2021-07-27)||67.98%|
|6 months (2021-04-27)||46.55%|
|1 year (2020-10-27)||33.79%|
|2 years (2019-10-25)||-31.67%|
|3 years (2018-10-23)||N/A|
|5 years (2016-10-23)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-25.63%|
|Return on equity TTM||-74.85%|
|Market capitalisation||$967.4 million|
TTM: trailing 12 months
There are currently 9.3 million Gossamer Bio shares held short by investors – that's known as Gossamer Bio's "short interest". This figure is 4.1% down from 9.7 million last month.
There are a few different ways that this level of interest in shorting Gossamer Bio shares can be evaluated.
Gossamer Bio's "short interest ratio" (SIR) is the quantity of Gossamer Bio shares currently shorted divided by the average quantity of Gossamer Bio shares traded daily (recently around 606818.14014407). Gossamer Bio's SIR currently stands at 15.27. In other words for every 100,000 Gossamer Bio shares traded daily on the market, roughly 15270 shares are currently held short.
However Gossamer Bio's short interest can also be evaluated against the total number of Gossamer Bio shares, or, against the total number of tradable Gossamer Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gossamer Bio's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Gossamer Bio shares in existence, roughly 120 shares are currently held short) or 0.1452% of the tradable shares (for every 100,000 tradable Gossamer Bio shares, roughly 145 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Gossamer Bio.
Find out more about how you can short Gossamer Bio stock.
We're not expecting Gossamer Bio to pay a dividend over the next 12 months.
Over the last 12 months, Gossamer Bio's shares have ranged in value from as little as $7.04 up to $14.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gossamer Bio's is 0.9831. This would suggest that Gossamer Bio's shares are less volatile than average (for this exchange).
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.